Intracorporal urinary diversion (ICD) provides superior postoperative outcomes compared to extracorporal urinary diversion (ECD). The investigators' hypothesis that ICD may provide clinical benefit is based on principles of less bowel and ureteral handling, superior operating room workflow, less exposure to the external environment, and optimal visualization with ICD while utilizing a smaller incision compared to ECD. ICD should have less bowel-related complications, lower pain scores allowing patients to be discharged from the hospital sooner and regain functional independence more quickly.
|Overal Status||Start Date||Phase||Study Type|
|Recruiting||April 25, 2018||N/A||Interventional|
Primary Outcome 1 - Measure: 90-day Post-Operative Complication Rate
Primary Outcome 1 - Time Frame: 90 days
- Biopsy-proven urothelial cancer being considered for RARC.
- Clinical stage T1-T4, N0-1, M0 or refractory carcinoma in situ.
- Subject must be already scheduled to have a RARC at the discretion of the surgeon and
with the patient's agreement.
- Inability to give informed consent
- Prior major abdominal and pelvic open surgical procedures that would preclude a safe
robotic approach, as determined by the treating surgeon.
- At the discretion of the treating surgeon, any pre-existing condition such as severe
chronic obstructive pulmonary disease that precludes a safe initiation or maintenance
of pneumoperitoneum over a prolonged period of time and during surgery.
- Age <18 or >99 years.
Minimum Age: 18 Years
Maximum Age: 99 Years
Healthy Volunteers: No
Name: Mark L Gonzalgo, MD, PhD
Role: Principal Investigator
Affiliation: University of Miami
|University of Miami
Miami, Florida 33136
Mark L Gonzalgo, MD, PhD